FDA relied on proprietary company data, charges Pfizer

Share this article:
Pfizer's charge that the FDA relied on proprietary company data on its Genotropin in approving rival Sandoz' human growth hormone product Omnitrope have been denied by the agency. It said Sandoz had to establish that "Omnitrope is highly similar to Genotropin without reference to proprietary data in Pfizer's Genotropin NDA."

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions